FDA seeks permanent future for rare pediatric priority review vouchers
The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?